[LCID Study Number: 20193097]
A031702: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
The purpose of this study is to test the good and bad effects of the drugs called cabozantinib, nivolumab and ipilimumab, when given in combination.
Disease/Condition: Genitourinary Cancer, Bladder Cancer, Renal Cancer
Department: Hematology and Oncology
Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421